Last reviewed · How we verify
HCV 796
At a glance
| Generic name | HCV 796 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects (PHASE2)
- Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men (PHASE1)
- Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796 (PHASE1)
- Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796 (PHASE1)
- Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine (PHASE1)
- Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults (PHASE1)
- Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects (PHASE1)
- HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCV 796 CI brief — competitive landscape report
- HCV 796 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI